Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients
Pediatric Endocrine Society 2020 Virtual Meeting

Rezolute profiled in Nature’s BioPharma Dealmakers, Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 editions

Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers

The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028

Activity of Xoma 358, an Inhibitor of Insulin Action Following Short-Term Administration to Congenital Hyperinsulinism Patients

ENDO 2017 Annual Meeting

XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial

ENDO 2015 Annual Meeting

Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: A potential new approach for the treatment of hyperinsulinemic hypoglycemia

mAbs 6:1, 262–272; January/February 2014; © 2014 Landes Bioscience

Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 307.

Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats

Diabetes, 60:1590–1598, May 2011

Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor–Stimulated Retinal Vascular Permeability

Hypertension, February 2009; 53:175-181